Live Webinar

Growth Disorder Care – Practical Solutions for Investigating and Treating Children with ISS and the Contribution of Genetic Studies in the Investigation of Growth Disorders

24 October 2025
From 14.00 to 15.00 CEST

Final Programme On demand Webinar
scroll-down-icon

ON DEMAND WEBINAR

Pre-webinar interview

Martin O. Savage

Post-webinar infographic

Launch: 31 October 2025

Back to Main page

Overview

Idiopathic short stature (ISS), the commonest cause of short stature and poor growth, is difficult to diagnose and is arbitrarily defined as a height <-2 SDS without an identified cause [Cutfield, 2018]. ISS remains a diagnosis of exclusion, but is a common label when investigations are complete. When treated with growth hormone, the response is widely variable, reflecting the heterogeneity of ISS, but generally improves adult height by approximately 4 cm [Cutfield, 2018]. The umbrella term of ISS covers children with many different causes for their short stature, including children who may have growth hormone resistance. Developing genetic analysis techniques are increasing the accuracy of diagnosis for many children [Storr, 2019]. Genetic investigations are increasingly showing positive results in populations of children with short stature. The development of next generation sequencing (NGS) has facilitated the technology and reduced the cost of these studies. Clinicians need education about the nature of meaningful genetic studies and notably, which children are likely to benefit from these studies. They are not indicated in all short children. There are certain features indicating that genetic studies are likely to be beneficial to diagnosis [Savage, Storr, 2021]. These will be explained.

Learning Objectives

At the end of the webinar, learners should be able to:

  • • Define ISS, and recognise ISS in the context of a differential diagnosis of growth disorders
  • • Consider AI, clinical skills and genetics to further diagnosis
  • • Recognise the value of personalised treatment of children with growth disorders
  • • Identify which genetic investigation can be of value
  • • Recall which children should have genetic studies
  • • Summarize the rates of positive genetic diagnosis in children with growth disorders

Target Audience

Paediatricians working in growth disorder management, general practitioners and specialist growth disorder nurses.

Language

English with simultaneous translation into Spanish and Korean

Continuing Medical Education
(CME)

The Growth Disorder Care – Practical Solutions for Investigating and Treating patients with ISS and the Contribution of Genetic Studies to the Investigation of Short Stature, Virtual, Italy 24/10/2025 – 24/10/2025 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

uems-eaccme-logo

The content of the Growth Disorder Care – Practical Solutions for Investigating and Treating patients with ISS and the contribution of genetic studies to the investigation of short stature has been certified by the CPD Certification Service as conforming to continuing professional development principles.

CME provider

MedEA Medical Education Academy

Senior Educational Programme Director: Flaminia Masprone

T 39 02 8295 8658

info@medeaacademy.com

Growth Disorder Care

24 October 2025 · from 14.00 to 15.00 CEST

Faculty

Richard JM Ross

Richard JM Ross

Emeritus Professor of Endocrinology
University of Sheffield
Sheffield, UK
Biography
Martin O. Savage

Martin O. Savage

Emeritus Professor of Paediatric Endocrinology
William Harvey Research Institute
Barts and the London School of Medicine and Dentistry
Queen Mary, University of London
London, UK
Biography
Helen Storr

Helen Storr

Professor of Paediatric Endocrinology
William Harvey Research Institute
Queen Mary, University of London
London, UK
Biography

International Committee

Raúl Calzada León

Raúl Calzada León

President of the Latin-American Society of Pediatric Endocrinology (SLEP)
Head of the Endocrinology Service
National Institute of Pediatrics
Mexico City, Mexico
Biography
Ana Elena Chiesa

Ana Elena Chiesa

Coordinator of the International Relations Commission
Latin American Society of Pediatric Endocrinology (SLEP)
Pediatric Endocrinologist
Department of Pediatrics
R. Gutiérrez Children's Hospital
Buenos Aires, Argentina
Biography
María Isabel Hernández C.

María Isabel Hernández C.

Coordinator of the Continuing Education Committee of the Latin American Society of Pediatric Endocrinology (SLEP)
Pediatric Endocrinologist and Assistant Professor
Department of Neurological Sciences
Institute of Neurosurgery Asenjo
Faculty of Medicine
University of Chile
Biography
Jeff Bolton

Jeff Bolton

Chair of Trustees
Child Growth Foundation
UK
Biography

Partnerships & Endorsements

Child Growth Foundation (CGF)

Latin American Society for Pediatric Endocrinology (SLEP)

With the Endorsement of the

British Society for Paediatric Endocrinology and Diabetes (BSPED)

Agenda

AGENDA

Final Programme

FUNDING

· Martin O. Savage ·

Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.  His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 60 countries and has published 482 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.

· Richard JM Ross ·

Richard JM Ross trained in medicine at The Royal London Hospital (1974-1979) and in Endocrinology at St Bartholomew’s Hospital, London (1983-1988). Appointed to Sheffield University in 1995 and is Emeritus Professor of Endocrinology, past Head of Section and currently theme lead for Diabetes, Endocrinology and Metabolism. Retired from clinical practice in 2021. Richard’s research and clinical interests are in pituitary and adrenal disease, transition endocrinology and the late effects of cancer. Richard was Chief Scientific Officer and Director on the Board of Diurnal Group Plc (2004-2022); overseeing its flotation in 2015 on the London Stock market (AIM) prior to its purchase by Neurocrine Biosciences in 2022. Served on the editorial boards of: Clinical Endocrinology (1996-2000), Growth & Growth Factors (1986-2006), Hormones (2004-2018), and J Clin Endocrinol Metab (2010-2014). Council member for the Society of Endocrinology (1999-2002), Editor Endocrinologist (2001-2004), Chair of CaHASE (2002-2015), member of the Bioscientifica Board (2006-2010), Society for Endocrinology Public Engagement Committee (2008-2011) and Nominations Committee (2010-2012). Executive Committee of the European Society of Endocrinology (2011-2015), Treasurer of the European Society of Endocrinology (2013-2015), The Growth Hormone Research Society Council (2011-2018), and The Pituitary Society Board of Directors (2019-). Received The Endocrine Societies “Outstanding Innovation Award” in 2021 and awarded the Clinical

· Helen Storr ·

Helen Storr is a Professor and Honorary Consultant in Paediatric Endocrinology at Queen Mary University London (QMUL) and Barts Health Trust, London. She completed a PhD in molecular endocrinology at the William Harvey Research Institute, Barts and the London School of Medicine funded by a Wellcome Trust Research Training Fellowship. Professor Storr was awarded the 2011 European Society for Paediatric Endocrinology (ESPE) Young Investigator Award and an NIHR Advanced Fellowship in 2019. Her clinical paediatric endocrine practice is broad with key clinical interests in disorders of growth. She leads an active programme of clinical and basic science research focusing on the recognition, diagnosis, and management of growth disorders in children. Key interests include the genetic diagnosis and molecular basis of growth disorders and growth hormone insensitivity. She is a member of the Editorial Board for the Journal of Clinical Endocrinology and Metabolism, member of the BSPED Research Group, medical advisor for the Child Growth Foundation (CGF) and Chairs the British Society For Paediatric Endocrinology and Diabetes (BSPED) Growth Disorders Special Interest Group.

· Raúl Calzada León ·

Raúl Calzada León has been Chief of the Pediatric Endocrinology Service in the National Institute of Pediatrics, Mexico, since 1993. He was former President of the Mexican Society of Nutrition and Endocrinology and of the Mexican Society of Pediatric Endocrinology and is now the current President of the Latin-American Society of Pediatric Endocrinology. As well as clinical practice, Professor Calzada León is an active teacher and lecturer in endocrinology, pediatric endocrinology and clinical biochemistry at the National and Autonomous University of Mexico and the Medicine School at the National Polytechnic Institute of Mexico and advises nationally on Mexican health standards. He is a member of numerous national, regional and international societies for Endocrinology and Pediatrics. Professor Calzada León has published widely on many aspects of pediatric endocrinology, particularly on research into growth hormone treatment, congenital hypothyroidism, precocious puberty and early β-cell damage in pediatric patients with obesity and diabetes. He has been a member of the editorial board of Pediatric Endocrinology Review.

· Ana Elena Chiesa ·

Ana Elena Chiesa is Coordinator of the International Relations Commission of the Latin American Society of Pediatric Endocrinology (SLEP), Researcher at the CONICET (Consejo Nacional de Investigaciones Científicas y Técnicas) and at the GCBA research council, Attending Physician at the Division of Endocrinology, HNRG and Neonatal Screening (NBS) Program Medical Coordinator at the FEI (Fundación de Endocrinologia Infantil) and at the Buenos Aires City Government, Argentina. Doctor Chiesa is interested in the basic and clinical aspects of the thyroid axis. Her work is focused on thyroid disease during the neonatal period, childhood and adolescence. She carries on her research in different aspects related to neonatal screening (NBS) of inapparent diseases at birth such as Congenital Hypothyroidism, Congenital Adrenal Hyperplasia, and Phenylketonuria among others, taking care of the follow-up of patients.

· Maria Isabel Hernández C. ·

Professor Dr María Isabel Hernández is Pediatric Endocrinologist and Professor of Pediatric Endocrinology at the Department of Neurological Science, Institute of Neurosurgery Asenjo and Institute of Maternal and Child Research, Faculty of Medicine, University of Chile. Coordinator of the Continuing Education Committee the Latin American Society of Pediatric Endocrinology and Chilean Society of Endocrinology and Diabetes.

Prof. Hernández´s main research interest is pituitary disease and special focus in pituitary tumors and follow up of pediatric patients after brain tumors treatment. She leads the Pediatric endocrinology unit of pituitary disease in the Institute of Neurosurgery in Chile, which is a referral center for pituitary disease in the country.

· Jeff Bolton ·

A BSc (Hons) and MBA graduate from Welsh universities, Jeff joined the pharmaceutical industry in 1990. Jeff first worked for Janssen-Cilag, where he performed a number of commercial and marketing management roles.

Jeff joined Pfizer in 2002 as Senior Brand Manager in the Endocrinology Team and transitioned into a European marketing role in 2006. Jeff became European Brand Director in 2010. Jeff left Pfizer in 2016 to start his own consultancy company, JRB Consultancy Services Ltd.

Jeff has been involved with growth conditions for over 20 years, and has won numerous awards, both national and international, for his role in developing campaigns and support information and materials for families affected by growth conditions. Jeff was the European lead for the development of the first growth prediction tool, iGRO, which was sponsored by Pfizer, and has since been rolled out in more than 25 countries.

Jeff has been a trustee of the Child Growth Foundation for over two years and became their Chair in 2022.

Join our Newsletter!

Stay in the know with our CME updates

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.